Press Releases Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 05:00:39 2025-12-08 EST			5-day change	1st Jan Change
107.38 ^CHF	+0.28%		+2.93%	+20.99%

02:29am	AlphaValue/Baader Europe Ups Novartis Price Target on 'Strong' Execution, 'Vigorous' Growth	MT
02:01am	NOVARTIS AG : Upgraded to Buy by JP Morgan	ZD

Press Releases

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS	11-25	GL
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)	11-24	GL
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets	11-20	GL
Novartis announces plans to build flagship manufacturing hub in North Carolina	11-19	GL
Novartis announces plans to build flagship manufacturing hub in North Carolina	11-19	GL
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance	11-12	GL
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan	11-12	AQ
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan	11-10	GL
Novartis : Earnings Document (novartis q3 2025 impact and sustainability update)	11-10	PU
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline	11-04	GL
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials	10-29	GL
Technical Advancement Required To Secure Patent: Delhi High Court Affirms	10-29	AQ
Novartis completes acquisition of Tourmaline Bio	10-28	GL
Novartis: Q3 Earnings Snapshot	10-28	AQ
Novartis announces expiration of Tourmaline Bio tender offer	10-28	GL
Novartis : Earnings Document (2025 10 interim financial report en)	10-28	PU
Novartis : Earnings Document (q3 2025 investor presentation)	10-28	PU
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance	10-28	GL
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases	10-27	AQ
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline	10-26	GL
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases	10-25	GL
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)	10-22	GL
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer	10-22	GL
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer	10-19	GL
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population	10-17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Novartis raises guidance and target price after strong execution

December 05, 2025 at 11:23 am

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 05:56 am